## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($188.12)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 4, Bearish: 3)

**1. BD faces hernia mesh lawsuit from Tela Bio**
- Source: MassDevice | 20251223T141325 | Bearish | Relevance: 100%
- Tela Bio has filed a lawsuit against BD, alleging anti-competitive practices in the U.S. surgical hernia mesh market. Tela Bio claims BD used its market dominance to exclude Tela's OviTex offering and punished hospitals for purchasing Tela's products through long-term contracts. This lawsuit builds on BD's history of legal challenges related to its hernia mesh devices, although the company continues to dispute allegations and produce mesh products.

**2. Does Becton Dickinsonâ€™s Recent Slide Create an Opportunity for Long Term Investors in 2025?**
- Source: Simply Wall Street | 20251222T200812 | Bullish | Relevance: 100%
- Becton Dickinson (NYSE: BDX) has seen its stock slide recently but may present a value opportunity for long-term investors. A Discounted Cash Flow analysis suggests the stock is currently undervalued by 39.7%, trading at a significant discount to its estimated fair value. While its Price to Earnings ratio is slightly above the industry average, the company's fundamentals, including its focus on higher-margin medical technologies and integration of acquisitions, indicate it's reasonably valued on earnings.

**3. BD and Penn Institute Ink Collaboration to Advance Immunotherapy**
- Source: The Globe and Mail | 20251222T190827 | Bullish | Relevance: 100%
- Becton, Dickinson and Company (BDX) has announced a collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to advance immunotherapy. Their partnership will focus on developing a high-parameter flow cytometry panel and conducting a study involving 1,000 people to understand the human immune system and support immune-mediated treatments. This initiative aims to translate complex immune data into actionable information for clinical care, strengthening BD's position in advanced flow cytometry and single-cell analysis.

**4. Trust Co. of Vermont Lowers Stake in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251223T124549 | Neutral | Relevance: 100%
- Trust Co. of Vermont decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 12.7% in Q3, selling 6,840 shares and holding 47,196 shares worth $8.83 million. The company reported quarterly EPS of $4.10 on $5.32 billion revenue, with analysts expecting $14.43 EPS for the fiscal year and a "Hold" consensus rating. Becton, Dickinson and Company also increased its quarterly dividend to $1.05.

**5. Becton, Dickinson accused of hindering competition in hernia mesh market**
- Source: Seeking Alpha | 20251222T230911 | Bearish | Relevance: 100%
- Tela Bio has filed a lawsuit accusing Becton, Dickinson (BDX) of hindering competition in the U.S. market for surgical hernia mesh. The lawsuit, filed on December 19th in a Philadelphia federal court, claims that Becton, Dickinson leveraged its dominant position in permanent hernia mesh to stifle competition.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | RBC Capital | $210 | $202 | +4% |
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | RBC Capital | main | Sector Perform |
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.00 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (2 raises, avg +5%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.8B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 12.3 |
| Current P/E | 13.1 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.0% to -0.4% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.4pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.44% (CS: 50) | Neutral |
| RSI_14 | 54.0 | Neutral |
| MACD Histogram | -0.27 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 1.033x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $195.66
- **Stop Loss:** $188.12 (3.9% risk)
- **Target:** $210.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 159
- **Position Value:** $31,109.94
- **Portfolio %:** 31.11%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*